Ulcerative Colitis Clinical Trial
— TRP-IBDOfficial title:
Multicentric, Double-blind, Placebo Controlled Clinical Trial With 5-hydroxytryptophan (5-HTP) in Patients With Inflammatory Bowel Disease in Clinical and Biologic Remission: Effect on Fatigue Scores
Verified date | January 2021 |
Source | University Hospital, Ghent |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This placebo cross-over trial aims to study the effect of the oral intake of an essential amino-acid 5-OH tryptophan, the precursor of serotonin, on the fatigue scores in IBD patients in deep clinical and biological remission.
Status | Completed |
Enrollment | 175 |
Est. completion date | March 3, 2021 |
Est. primary completion date | February 23, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - The subject is male or female and aged 18 to 60 yrs (inclusive) - The subject has a documented Crohn's disease or ulcerative colitis - The subject is, in the opinion of the investigator, capable of understanding and complying protocol requirements - The subject is in clinical remission over last 3 months (based on physician global assessment) - The subject is in clinical remission at day 0 based on validated scores (SCCAI = 2 for ulcerative colitis or Harvey Bradshaw index = 4 for Crohn's disease). - The subject reports fatigue on a quantified scale (visual analogue scale 0 - 10) of 5 or more - The subject is treated with biologicals and/or immunosuppressives since at least 6 months with stable dose over last 3 months - The subject is in biologic remission at day 0: CRP < 10 mg/l and faecal calprotectin value < 250 mg/kg Exclusion Criteria: - The subject has a clinical validated depression - The subject is taking antidepressives or neuroleptics - The subject has a psychiatric comorbidity - The subject has important comorbidities: cardiovascular disease, obstructive lung pathology, neoplasia or other - The subject has a documented Anemia (based on lab results including Hb < 12-13 g/dl respectively for saturation index < 20%, Vit B12 < 148 pmol/L or folic acid < 6 nmol/L) - The subject has a documented hypothyreoidea (documented by a recent lab result including TSH) - The subject reports an infection within 2 weeks before inclusion - The subject reports any change in IBD medication (biologicals and immunosuppressives) in the last 12 weeks before inclusion - The subject was treated with oral corticosteroids during the last 8 weeks before enrolment - The subject reports an ongoing pregnancy or breastfeeding - The subject has a history of lymphoproliferative disease or cancer other than basocellular skin cancer - The subject underwent surgery in the past 12 weeks prior to the screening visit - The subject reports a history of clinically significant drug abuse (defined as any illicit drug use) or alcohol abuse within 1 year prior to inclusion |
Country | Name | City | State |
---|---|---|---|
Belgium | AZ Imelda | Bonheiden | |
Belgium | CHU Saint-Pièrre | Brussel | |
Belgium | UCL Saint-Luc | Brussel | |
Belgium | UZ Brussel | Brussel | |
Belgium | ULB Erasme | Brussels | |
Belgium | AZ Maria Middelares | Ghent | |
Belgium | AZ Sint-Lucas | Ghent | |
Belgium | Ghent University Hospital | Ghent | |
Belgium | UZ Leuven | Leuven | |
Belgium | CHU Liège | Liège | |
Belgium | CHU Namur | Namur | |
Belgium | AZ Damiaan | Oostende | |
Belgium | AZ Nikolaas | Sint-Niklaas |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Ghent |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Visual Analog Scale (VAS) after intervention | Patients are asked to indicate their fatigue level on a VAS-scale from 0 to 10, where 0 represents no fatigue and where 10 indicates the patient suffers from severe fatigue. | weekly, 16 weeks | |
Secondary | Changes in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score | The questionnaire is a self-assessment that need to be completed without external help. The FACIT-F questionnaire measures the fatigue of the patient and will be filled in at week 0, week 8 and week 16. The FACIT Fatigue scale ranges from 0 to 52, with high scores indicating higher levels of fatigue. | week 0, week 8 and week 16 | |
Secondary | Changes in short Depression Anxiety and Stress Scale (DASS21) | The questionnaire is a self-assessment that need to be completed without external help. The DASS questionnaire measures depression and anxiety and will be filled in at week 0, week 8 and week 16. The questionnaire contains 7 items per scale, the maximum score for depression, anxiety and stress will be 21. The higher the score of the questionnaire, the more the patient suffers from depression, anxiety and stress. | week 0, week 8 and week 16 | |
Secondary | Change in Adapted International Physical Activity Questionnaire (IPAQ) | The adapted IPAQ questionnaire measures the physical activity and will be filled in at week 0, week 8 and week 16. | week 0, week 8 and week 16 | |
Secondary | Changes in serum 5-HydroxyTryptophane (5-HTP) by treatment | The possible effect of Levotonine administration on the serum 5-HTP levels will be measured. | Week 0, week 8 and week 16 | |
Secondary | Changes in serum 5-hydroxyindoleacetic acid by treatment | The possible effect of Levotonine administration on the serum 5-hydroxyindoleacetic levels will be measured. | Week 0, week 8 and week 16 | |
Secondary | Changes in serum serotonin levels by treatment | The possible effect of Levotonine administration on the serum serotonin levels will be measured. | Week 0, week 8 and week 16 | |
Secondary | Changes in serum melatonin levels by treatment | The possible effect of Levotonine administration on the serum melatonin levels will be measured. | Week 0, week 8 and week 16 | |
Secondary | Changes in faecal microbiome/metabolome | since the intestinal bacteria can process tryptophane, changes in the faecal microbiome/metabolome can be possibly caused by the administration of levotonine. | Week 0, week 8 and week 16 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |